摘要
目的分析全胸腔镜下左房黏液瘤切除手术的效果,探索其临床应用价值。方法入选从2016年8月至2020年8月在我院收治左房黏液瘤50例,在全身麻醉下行全胸腔镜下左房黏液瘤切除术,评估围手术期风险、并发症、手术效果。术后7 d及术后3、6、12个月、每年复查心脏彩超。结果全组手术均成功,无围手术死亡,1例术后胸壁切口出血二次止血,2例发生切口感染,1例发生气胸,1例术前脑梗死,1例下肢动脉栓塞行取栓术。平均住院时间为(7.13±3.96)d,平均重症监护病房住院时间为(1.52±1.06)d,术后平均胸腔引流液(136.65±50.66)mL。平均随访时间为30个月,1例出现复发,再次手术切除,其余没有残留或复发肿瘤的证据。结论全胸腔镜下左心房黏液瘤切除术是一种安全、可重复的手术,可被视为替代标准胸骨切开术的有效肿瘤切除方法。
Objective To analyze the effect of left atrial myxoma resection under Full thoracoscopic surgery and explore its clinical application value.Methods From August 2016 to August 2020,50 patients with left atrial myxoma were admitted to the author's hospital,under general anesthesia under thoracoscopic left atrial myxoma resection,to evaluate the perioperative risks,complications,and surgical effects.Cardiac color Doppler ultrasound was reviewed 7 days after surgery and 3,6,and 12 months after surgery.Results All operations were successful,no perioperative death occurred.One case of postoperative chest wall incision hemorrhage to stop bleeding,two cases of incision infection,one case of pneumothorax,one case of preoperative cerebral infarction,and one case of lower limb arterial embolism underwent embolectomy surgery.The average length of stay was(7.13±3.96)days,the length of stay in the intensive care unit was(1.52±1.06)days,and the average postoperative pleural drainage was(136.65±50.66)mL.The average follow-up time was 30 months.One case had a recurrence and was resected again.The rest had no evidence of residual or recurring tumors.Conclusion Total thoracoscopic resection of left atrial myxoma is a safe and reproducible operation,which can be regarded as an effective tumor resection method instead of standard sternotomy.
作者
李春平
任飞
丁杭
黄烽
LI Chunping;REN Fei;DING Hang;HUANG Feng(Department of Cardiovascular Surgery,Fujian Province Hospital,Provincial Clinical Medical College of Fujian Medical University,Fuzhou 350001,China)
出处
《中国医药指南》
2021年第33期100-101,共2页
Guide of China Medicine
基金
福建省2013-2014年度国家临床重点专科建设项目(国卫办医函【2013】544)
关键词
左房黏液瘤
胸腔镜
微创
体外循环
Left atrial myxoma
Thoracoscopy
Minimally invasive
Cardiopulmonary bypass
